Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Serial pharmacokinetic (PK) sampling in 1159 patients from TRITON-TIMI 38 was undertaken. A multilinear regression model was used to quantitatively predict prasugrel's active metabolite (Pras-AM) concentrations from its 2 downstream inactive metabolites. Population-based methods were then applied to Pras-AM concentration data to characterize the PK. The potential influence of body weight, body mass index, age, sex, renal function, diabetes, tobacco use, and other disease status on Bayesian estimates of Pras-AM exposures was assessed. The PK of Pras-AM was adequately described by a multicompartmental model and consistent with results from previous studies. The systemic exposure of prasugrel was not appreciably affected by body mass index, gender, diabetes, smoking, and renal impairment. Pras-AM mean exposure in patients weighing <60 kg (4.1%) was 30% (90% confidence interval [CI] 1.16-1.45) higher than exposure in patients > or =60 kg. Mean Pras-AM exposures for patients > or =75 years (10.5%) were 19% (90% CI: 1.11-1.28) higher compared with patients <75 years.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0091270009337942 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The chemoprotective effect of anti-platelet agents on cancer incidence in people with non-alcoholic fatty liver disease (NAFLD): a retrospective cohort study.
BMC Med
December 2024
Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
Article Synopsis
- Non-alcoholic fatty liver disease (NAFLD) is linked to higher rates of liver and obesity-related cancers, prompting researchers to investigate the protective effects of aspirin and other anti-platelet drugs on these cancers.
- A study analyzed medical records of adults with NAFLD to compare the cancer incidence between those taking antiplatelet medication for at least a year versus those who weren't, following them for five years.
- Results indicated that antiplatelet use significantly lowered the risk of obesity-related cancers, including hepatocellular carcinoma (HCC), breast, pancreatic, and colorectal cancers, with aspirin alone showing a major decrease in HCC incidence.
Ticagrelor vs Prasugrel for Acute Coronary Syndrome in Routine Care.
JAMA Netw Open
December 2024
Department of Cardiology, German Heart Center Munich, Technical University of Munich, Munich, Germany.
Importance: In patients with acute coronary syndrome (ACS) undergoing invasive treatment, ticagrelor and prasugrel are guideline-recommended P2Y12 receptor inhibitors. The ISAR-REACT5 randomized clinical trial demonstrated superiority for prasugrel, although concerns were raised about the generalizability of some underpowered subgroup analyses.
Objectives: To emulate a randomized clinical trial evaluating the safety and effectiveness of ticagrelor vs prasugrel under the conditions of routine care in individuals with ACS planned to undergo an invasive treatment strategy.
Nonvitamin K Anticoagulants: Risk of Bleeding When Interacting With Other Medications: A Cohort Study From Medicare.
Clin Cardiol
October 2024
Department of Pharmacotherapy, University of Utah, Salt Lake City, Utah, USA.
Introduction: Patients on nonvitamin K antagonist (NVKA) are usually taking other drugs. Potential interaction may increase the gastrointestinal (GI) bleeding risk associated with NVKA.
Methods: Observational cohort study using Medicare data from 2017 to 2020.
Effectiveness of Clopidogrel vs Alternative P2Y Inhibitors Based on the ABCD-GENE Score.
J Am Coll Cardiol
April 2024
Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, Florida, USA. Electronic address:
Background: An ABCD-GENE (age, body mass index, chronic kidney disease, diabetes, and CYP2C19 genetic variants) score ≥10 predicts reduced clopidogrel effectiveness, but its association with response to alternative therapy remains unclear.
Objectives: The aim of this study was to evaluate the association between ABCD-GENE score and the effectiveness of clopidogrel vs alternative P2Y inhibitor (prasugrel or ticagrelor) therapy after percutaneous coronary intervention (PCI).
Methods: A total of 4,335 patients who underwent PCI, CYP2C19 genotyping, and P2Y inhibitor treatment were included.
Population Pharmacokinetic/Pharmacodynamic Models for P2Y12 Inhibitors: A Systematic Review and Clinical Appraisal Using Exposure Simulation.
Clin Pharmacokinet
March 2024
Drug Clinical Trial Center, Peking University Third Hospital, Beijing, 100191, China.
Article Synopsis
- The study examines the relationship between plasma levels of P2Y12 inhibitors (clopidogrel, prasugrel, and ticagrelor) and the associated risks of bleeding, which affect their therapeutic effectiveness.
- Researchers collected and summarized population pharmacokinetics/pharmacodynamics (PopPKPD) models to investigate how specific individual characteristics influence plasma concentrations and bleeding risks.
- Findings suggest that factors like gender, weight, and age can greatly alter drug exposure in certain populations, leading to a recommendation to lower the ticagrelor dose to 60 mg bid for certain high-risk groups to minimize bleeding without increasing heart attack risk.